ロード中...
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the number of DPP-4 inhibitors has increased and DPP-4 inhibitors have developed into an important drug class. DPP-4 inhibitors act by increasing endogenous GLP-1 and GIP co...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3540954/ https://ncbi.nlm.nih.gov/pubmed/23319869 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S23166 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|